Godavari Drugs Intrinsic Value
Godavari Drugs (GODAVARI) median intrinsic value is ₹100.00 from 9 valuation models (range ₹37–₹212), vs current price ₹123.95 — -19.3% downside (Trading Above Median Value), margin of safety -24.0%. For current market price and key ratios, visit GODAVARI stock price BSE.
GODAVARI Valuation Methods Summary — DCF, Graham Number & P/E
Godavari Drugs intrinsic value across 9 models vs current price ₹123.95 — upside/downside and value range per method. Analyse Godavari Drugs ownership structure to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹119.46 | ₹95.57 - ₹143.35 | -3.6% | EPS: ₹5.43, Sector P/E: 22x |
| Book Value Method | asset | ₹142.00 | ₹127.80 - ₹156.20 | +14.6% | Book Value/Share: ₹71.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹212.00 | ₹190.80 - ₹233.20 | +71.0% | Revenue/Share: ₹106.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹100.00 | ₹90.00 - ₹110.00 | -19.3% | EBITDA: ₹10.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹149.42 | ₹119.54 - ₹179.30 | +20.5% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹37.19 | ₹33.47 - ₹40.91 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹77.41 | ₹69.67 - ₹85.15 | -37.5% | Revenue Growth: -9.9%, Adj P/E: 14.3x |
| ROE Based Valuation | profitability | ₹61.98 | ₹55.78 - ₹68.18 | -50.0% | ROE: 5.6%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹93.14 | ₹83.83 - ₹102.45 | -24.9% | EPS: ₹5.43, BVPS: ₹71.00 |
GODAVARI Intrinsic Value vs Market Price — All Valuation Models
Godavari Drugs fair value range ₹37–₹212 vs current market price ₹123.95 across 9 valuation models. Read Godavari Drugs dividend policy for the complete payout history and dividend yield track record.
GODAVARI Intrinsic Value Analysis — Undervalued or Overvalued?
Godavari Drugs median intrinsic value ₹100.00, current price ₹123.95 — Trading Above Median Value by 19.3%, margin of safety -24.0%.
What is the intrinsic value of GODAVARI?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Godavari Drugs (GODAVARI) is ₹100.00 (median value). With the current market price of ₹123.95, this represents a -19.3% variance from our estimated fair value.
The valuation range spans from ₹37.19 to ₹212.00, indicating ₹37.19 - ₹212.00.
Is GODAVARI undervalued or overvalued?
Based on our multi-method analysis, Godavari Drugs (GODAVARI) appears to be trading above median value by approximately 19.3%.
GODAVARI Financial Health — Key Ratios vs Industry Benchmarks
Godavari Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.80 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 5.6% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 10.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.53x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
GODAVARI Cash Flow Quality — Operating & Free Cash Flow
Godavari Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹11 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹18 Cr | ₹12 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹13 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹11 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |